Gilead Sciences, Inc. GILD announced that it will acquire clinical-stage biopharmaceutical company, CymaBay Therapeutics, Inc. CBAY, for $32.50 per share in cash or a total equity value of $4.3 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CBaySystems is a leading provider of technology-enabled clinical documentation services company. CBay serves healthcare providers with a broad range of solutions including voice capture, speech ...

And CBAY stock investors are closely watching. CBAY Stock: 2024 Could Be A Game-Changer CymaBay has had a really good year. In November, the company's drug, called seladelpar, emerged as the ...